产品说明书

Vorapaxar

Print
Chemical Structure| 618385-01-6 同义名 : 沃拉帕沙(MK-5348) ;SCH 530348;MK-5348
CAS号 : 618385-01-6
货号 : A824083
分子式 : C29H33FN2O4
纯度 : 99%+
分子量 : 492.582
MDL号 : MFCD16038876
存储条件:

粉末 Keep in dark place,Inert atmosphere,Room temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 25 mg/mL(50.75 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Protease-activated receptor 1 (PAR1) is a thrombin-activated receptor that contributes to inflammatory responses at mucosal surfaces[5]. Vorapaxar is an orally effective thrombin receptor (par-1) antagonist with a Ki value of 8.1 nM in cell-free assay[6]. The compound showed potent inhibition of thrombin-induced platelet aggregation with an IC50 of 47 nM and haTRAP-induced platelet aggregation with an IC50 of 25 nM, whereas it showed no inhibition of platelet aggregation induced by other agonists such as ADP, collagen, and a PAR-4 agonist peptide[6]. In additional functional assays, vorapaxar inhibited thrombin-induced calcium transient in human coronary artery smooth muscle cells (HCASMC) with a Ki of 1.1 nM, it also inhibited thrombin-stimulated thymidine incorporation in HCASMC with a Ki of 13 nM[6]. Pharmacokinetic profiling of vorapaxar was done in rat and monkey models. Following oral administration, vorapaxar was well absorbed in rat (68%; 10 mg/kg) and in monkey (82%; 1 mg/kg) models. Tmax was observed at about 3 h in rats and 1 h in monkeys. The elimination half-life was 5.1 h in rats and 13 h in monkeys. The oral bioavailability was 33% in rats and 86% in monkeys[6]. In an ex vivo cynomolgus monkey model of platelet aggregation, vorapaxar was 30 times more potent than the initial development candidate in the series, showing complete obliteration of agonist induced platelet activation at 0.1 mg/kg with >24 h duration of activity (versus comparable efficacy at 3 mg/kg for the initial candidate) [6].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.03mL

0.41mL

0.20mL

10.15mL

2.03mL

1.02mL

20.30mL

4.06mL

2.03mL

参考文献

[1]Kehinde O, Kunle R. Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction. J Pharm Bioallied Sci. 2016 Apr-Jun;8(2):98-105.

[2]Khoufache K, Berri F, et al. PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest. 2013 Jan;123(1):206-14.

[3]Chackalamannil S, Wang Y, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008 Jun 12;51(11):3061-4.

[4]Vorapaxar

[5]Khoufache K, Berri F, Nacken W, Vogel AB, Delenne M, Camerer E, Coughlin SR, Carmeliet P, Lina B, Rimmelzwaan GF, Planz O, Ludwig S, Riteau B. PAR1 contributes to influenza A virus pathogenicity in mice. J Clin Invest. 2013 Jan;123(1):206-14. doi: 10.1172/JCI61667. Epub 2012 Dec 3. PMID: 23202729; PMCID: PMC3533265.

[6]Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, Boykow G, Hsieh Y, Palamanda J, Agans-Fantuzzi J, Kurowski S, Graziano M, Chintala M. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008 Jun 12;51(11):3061-4. doi: 10.1021/jm800180e. Epub 2008 May 1. PMID: 18447380.